Biogen Inc. $BIIB Stock Position Increased by CWA Asset Management Group LLC

CWA Asset Management Group LLC raised its position in shares of Biogen Inc. (NASDAQ:BIIB) by 9.6% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 32,534 shares of the biotechnology company’s stock after purchasing an additional 2,841 shares during the period. CWA Asset Management Group LLC’s holdings in Biogen were worth $5,726,000 at the end of the most recent quarter.

Other large investors also recently made changes to their positions in the company. Elevation Point Wealth Partners LLC bought a new position in Biogen in the 2nd quarter worth approximately $25,000. Accredited Wealth Management LLC raised its stake in Biogen by 1,233.3% during the 3rd quarter. Accredited Wealth Management LLC now owns 200 shares of the biotechnology company’s stock valued at $28,000 after acquiring an additional 185 shares in the last quarter. WFA of San Diego LLC bought a new stake in Biogen during the 2nd quarter valued at $32,000. True Wealth Design LLC boosted its position in Biogen by 62.9% during the 3rd quarter. True Wealth Design LLC now owns 233 shares of the biotechnology company’s stock worth $33,000 after acquiring an additional 90 shares during the period. Finally, GoalVest Advisory LLC acquired a new position in Biogen during the 4th quarter worth $35,000. Institutional investors and hedge funds own 87.93% of the company’s stock.

More Biogen News

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: New real‑world data presented at AD/PD show high long‑term persistence on lecanemab, with 78.4% on therapy at 18 months, ~67.3% at 24 months and 94% of clinical‑trial completers entering the open‑label extension — supports ongoing commercial uptake and durability of benefit for LEQEMBI. Article Title
• Positive Sentiment: Late‑breaking data and regulatory momentum for other programs: litifilimab Phase 2 AMETHYST results will be presented at AAD (recent Breakthrough Therapy designation for CLE), and Biogen completed a BIIB080 imaging Phase 1 study — both reinforce pipeline diversification beyond Alzheimer’s. Article Title
• Positive Sentiment: Biogen launched a Phase 3 fumarate study targeting pediatric MS — a potential growth vector for the MS franchise if successful. Article Title
• Neutral Sentiment: Short‑interest reports in recent feeds show anomalous/zero values and NaN changes — appears to be data noise rather than meaningful squeeze risk; monitor reliable exchanges for confirmation. (internal short‑interest entries)
• Negative Sentiment: A securities class action has been certified in the District of Massachusetts on behalf of Biogen purchasers — this increases legal overhang and potential near‑term headline risk. Article Title

Biogen Price Performance

Shares of NASDAQ:BIIB opened at $181.46 on Friday. The company has a market cap of $26.63 billion, a price-to-earnings ratio of 20.60, a PEG ratio of 1.46 and a beta of 0.15. The business has a 50 day moving average price of $184.06 and a 200 day moving average price of $168.47. The company has a quick ratio of 2.03, a current ratio of 2.68 and a debt-to-equity ratio of 0.34. Biogen Inc. has a twelve month low of $110.04 and a twelve month high of $202.41.

Biogen (NASDAQ:BIIB) last issued its quarterly earnings results on Friday, February 6th. The biotechnology company reported $1.99 EPS for the quarter, topping analysts’ consensus estimates of $1.61 by $0.38. The company had revenue of $2.28 billion during the quarter, compared to analyst estimates of $2.21 billion. Biogen had a return on equity of 12.64% and a net margin of 13.07%.The company’s quarterly revenue was down 7.2% compared to the same quarter last year. During the same period in the previous year, the company earned $3.44 earnings per share. Biogen has set its FY 2026 guidance at 15.250-16.250 EPS. Research analysts predict that Biogen Inc. will post 15.83 earnings per share for the current year.

Insider Transactions at Biogen

In other news, insider Priya Singhal sold 2,660 shares of the business’s stock in a transaction dated Monday, February 9th. The shares were sold at an average price of $199.83, for a total transaction of $531,547.80. Following the transaction, the insider owned 8,043 shares in the company, valued at approximately $1,607,232.69. The trade was a 24.85% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 0.18% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

BIIB has been the topic of a number of research analyst reports. Weiss Ratings reissued a “hold (c-)” rating on shares of Biogen in a report on Monday, December 29th. Morgan Stanley set a $190.00 price objective on shares of Biogen in a report on Sunday, February 8th. Oppenheimer increased their target price on shares of Biogen from $205.00 to $225.00 and gave the company an “outperform” rating in a research report on Friday, January 30th. TD Cowen raised their target price on shares of Biogen from $175.00 to $215.00 and gave the company a “buy” rating in a research note on Monday, February 9th. Finally, The Goldman Sachs Group reaffirmed a “buy” rating on shares of Biogen in a research note on Monday, February 9th. Twelve analysts have rated the stock with a Buy rating, fifteen have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $205.31.

Biogen Company Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.